Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)

Funding Opportunity RFA-CA-24-021 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) soliciting UG3/UH3 applications for the pediatric arm of the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The overall goal of the NOFO is to advance new cell therapy strategies into clinical testing for the treatment of solid tumors in pediatric cancer patients (18 years or younger). The successful applications will add to -the newly established Cancer Adoptive Cellular Therapy (Can-ACT) Network, dedicated to developing innovative cell therapy approaches for the treatment of solid tumors in pediatric and adult tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.